262 related articles for article (PubMed ID: 24142828)
1. Will biosimilars gain momentum?
Hirsch BR; Lyman GH
J Natl Compr Canc Netw; 2013 Oct; 11(10):1291-7. PubMed ID: 24142828
[TBL] [Abstract][Full Text] [Related]
2. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
3. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars: the science of extrapolation.
Weise M; Kurki P; Wolff-Holz E; Bielsky MC; Schneider CK
Blood; 2014 Nov; 124(22):3191-6. PubMed ID: 25298038
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: Implications for Clinical Practice.
Rifkin RM; Peck SR
J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar agents in oncology/haematology: from approval to practice.
Niederwieser D; Schmitz S
Eur J Haematol; 2011 Apr; 86(4):277-88. PubMed ID: 21175852
[TBL] [Abstract][Full Text] [Related]
9. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
10. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
Li E; Lobaina E
J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
[TBL] [Abstract][Full Text] [Related]
11. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars: are they ready for primetime in the United States?
Hirsch BR; Lyman GH
J Natl Compr Canc Netw; 2011 Aug; 9(8):934-42; quiz 943. PubMed ID: 21900222
[TBL] [Abstract][Full Text] [Related]
13. The Role of Biosimilars.
Zelenetz AD; Becker PS
J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):626-9. PubMed ID: 27226500
[TBL] [Abstract][Full Text] [Related]
14. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
15. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
16. Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.
Abboud CN; Lang N; Fung H; Lammerich A; Buchner A; Liu P; Mueller U; Pettengell R; Diel IJ; Link H; Pathak A
Support Care Cancer; 2019 Jul; 27(7):2569-2577. PubMed ID: 30443809
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
18. Current Status of Biosimilars in Oncology.
Camacho LH
Drugs; 2017 Jun; 77(9):985-997. PubMed ID: 28477160
[TBL] [Abstract][Full Text] [Related]
19. Current market and regulatory landscape of biosimilars.
Bhatt V
Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
[TBL] [Abstract][Full Text] [Related]
20. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
